On August 6, 2026, Eli Lilly and Company filed 14 patent infringement lawsuits in the U.S. District Court for the District of Delaware against drugmakers seeking Food and Drug Administration (FDA) approval to sell generic versions of Mounjaro and Zepbound, its two tirzepatide medicines. Each defendant had submitted an abbreviated new drug application (ANDA), the application a generic manufacturer files to copy an approved drug, certifying that Lilly's patents are invalid or will not be infringed.
The 14 cases cover 29 ANDAs and ten patents, and all are before Judge Jennifer L. Hall. As of November 18, 2026, every defendant has answered, ten of them with counterclaims against Lilly. Under federal drug law, FDA cannot make any of these approvals effective before November 13, 2029 unless the court first rules the patents invalid or not infringed.
Why fourteen suits on one day
Tirzepatide was a new active ingredient when FDA approved Mounjaro on May 13, 2022. For a new chemical entity, the law bars any ANDA that refers to the drug for five years after approval, with one exception. After four years, an applicant may file if its application certifies that a listed patent is invalid or will not be infringed. This is called a Paragraph IV certification, after the clause of the statute that defines it. FDA's Orange Book, its register of approved drugs and their patents, lists the same new chemical entity exclusivity, expiring May 13, 2027, for both Mounjaro and Zepbound, although Zepbound was approved in November 2023.
Four years after Mounjaro's approval was May 13, 2026. FDA's list of Paragraph IV certifications records that date as the first submission of such applications for both brands, and counts up to 13 ANDAs for the Mounjaro autoinjector and up to 12 for Zepbound's, depending on strength.
An applicant that makes a Paragraph IV certification must notify the patent holder. Lilly received the notice letters in these cases between July 1 and July 16, 2026. A patent holder that sues within 45 days of receiving notice holds back FDA approval, and Lilly filed all 14 complaints on August 6, inside every one of those windows. Each complaint pleads that submitting the ANDA was itself an act of infringement under 35 U.S.C. 271(e)(2)(A), the provision that lets a patent holder sue before any generic product reaches the market.
Why the stay runs to November 2029
A timely suit ordinarily keeps FDA from making an approval effective for 30 months from the patent holder's receipt of notice. Counted from these notices, that would have ended in January 2029. When the suit comes in the fifth year after a new chemical entity's approval, the statute extends the 30 months until seven and a half years have passed since that approval. Seven and a half years after May 13, 2022 is November 13, 2029, and every one of the 14 dockets records that date as its stay deadline.
The stay ends sooner if the district court decides before then that the patents are invalid or not infringed, in which case approval can take effect from the date of the judgment. The stay governs when an approval can take effect, not whether FDA reviews the applications in the meantime.
The ten patents
All ten are listed in the Orange Book for Mounjaro, Zepbound or both:
- U.S. Patent No. 9,474,780, "GIP and GLP-1 Co-agonist Compounds," issued October 25, 2016, expires May 13, 2036. Listed for both.
- U.S. Patent No. 11,357,820, "GIP/GLP1 Agonist Compositions," issued June 14, 2022, expires June 14, 2039. Listed for both.
- U.S. Patent No. 11,918,623, "GIP/GLP1 Agonist Compositions," issued March 5, 2024, expires June 14, 2039. Listed for Zepbound.
- U.S. Patent No. 12,295,987, "Methods of Using a GIP/GLP1 Co-agonist for Diabetes," issued May 13, 2025, expires December 30, 2041. Listed for Mounjaro.
- U.S. Patent No. 12,343,382, "Methods of Using a GIP/GLP1 Co-agonist for Therapy," issued July 1, 2025, expires July 22, 2039. Listed for both.
- U.S. Patent No. 12,453,755, "GIP/GLP1 Agonist Compositions," issued October 28, 2025, expires June 14, 2039. Listed for Mounjaro.
- U.S. Patent No. 12,453,756, "GIP/GLP1 Agonist Compositions," issued October 28, 2025, expires June 14, 2039. Listed for both.
- U.S. Patent No. 12,453,758, "Methods of Using a GIP/GLP1 Co-agonist for Diabetes," issued October 28, 2025, expires July 22, 2039. Listed for Zepbound.
- U.S. Patent No. 12,616,740, "Methods of Using a GIP/GLP1 Co-agonist for Therapy," issued May 5, 2026, expires July 22, 2039. Listed for both.
- U.S. Patent No. 12,629,404, "GIP/GLP1 Agonist Compositions," issued May 19, 2026, expires June 14, 2039. Listed for both.
The '780 patent is the only one the Orange Book lists as claiming the drug substance, tirzepatide itself. Seven complaints assert it: those against Amneal, Dr. Reddy's, Eugia, Hikma, MSN, Rio and Sandoz. The other seven assert the remaining nine patents and not the '780. The complaints do not say why.
In every case Lilly asks the court to order that any FDA approval of the defendant's ANDAs take effect no earlier than the expiration of the last asserted patent, including any extensions, and to bar the defendant from selling its generic before then. It also asks for damages if a defendant launches before that date, and for attorneys' fees. FDA's Paragraph IV list gives the last qualifying patent expiration as December 30, 2041 for Mounjaro and July 22, 2039 for Zepbound.
The fourteen cases
Unless noted, an application covers the single-dose autoinjector pen in all six of its strengths, and the first ANDA number listed is for Mounjaro and the second for Zepbound. Dates are in 2026, and status is as of November 18.
- Alembic (No. 1:26-cv-00972): Alembic Pharmaceuticals Limited of India and Alembic Pharmaceuticals, Inc. ANDAs 221547 and 221542. Notice received July 13. Answered with counterclaims October 19, and Lilly amended its complaint November 9.
- Amneal (No. 1:26-cv-00973): Amneal Pharmaceuticals LLC and Amneal Pharmaceuticals, Inc. ANDAs 221733 and 221732. Notice received July 13. Lilly amended its complaint August 13 to add Adalvo Limited as a defendant. Answered with counterclaims November 16.
- Aspiro (No. 1:26-cv-00974): Aspiro Pharma Limited of India. ANDAs 221575 and 221574. Notice received July 16. Lilly amended its complaint August 13 to add Hetero Labs Limited and Hetero USA, Inc. as defendants. Answered with counterclaims November 16.
- Biocon (No. 1:26-cv-00976): Biocon Pharma Limited and Biocon Limited of India, and Biocon Pharma, Inc. ANDAs 219842 and 221378. Notice received July 9. Answered October 12.
- Dr. Reddy's (No. 1:26-cv-00977): Dr. Reddy's Laboratories, Limited of India and Dr. Reddy's Laboratories, Inc. ANDAs 220663 and 220664, covering autoinjectors and also vials in five strengths. Notice received July 15. Answered with counterclaims October 13.
- Eugia (No. 1:26-cv-00978): Eugia Pharma Specialities Limited and Aurobindo Pharma Limited of India, with Eugia US, LLC and Aurobindo Pharma U.S.A., Inc. Three ANDAs, 221740, 221742 and 221741, covering Mounjaro and Zepbound autoinjectors and Zepbound single-dose vials, each at two strengths. First notice received July 6. Answered with counterclaims October 7.
- Galenicum (No. 1:26-cv-00980): Galenicum Health S.L.U. of Spain. ANDAs 221515 and 221514. First notice received July 9. Answered September 8.
- Hikma (No. 1:26-cv-00981): Hikma Pharmaceuticals USA Inc. ANDAs 220241 and 220324. Notice received July 7. Lilly amended its complaint August 13. Answered with counterclaims October 19.
- Hybio (No. 1:26-cv-00982): Hybio Pharmaceutical Co. Limited of China and Hybio Pharmaceutical (US) Co. Limited. ANDAs 221683 and 221684. Notice received July 15. Answered October 29.
- Macleods (No. 1:26-cv-00984): Macleods Pharmaceuticals Limited of India and Macleods Pharma USA, Inc. ANDAs 221768 and 221771, covering autoinjectors and also KwikPen multi-dose pens at two strengths. First notice received July 1. Lilly amended its complaint September 9. Answered with counterclaims November 13.
- MSN (No. 1:26-cv-00985): MSN Laboratories Private Limited of India and MSN Pharmaceuticals Inc. ANDAs 221718 and 221719, covering vials in all six strengths and an autoinjector at one strength. Notice received July 16. Answered with counterclaims November 9.
- Rio (No. 1:26-cv-00986): Rio Biopharmaceuticals, Inc. and EMS S/A of Brazil. ANDAs 219641 and 220816. Notice received July 9. Answered with counterclaims November 16.
- Sandoz (No. 1:26-cv-00987): Sandoz Inc. ANDAs 218833 and 221376. First notice received July 1. Answered with counterclaims October 9.
- Zydus (No. 1:26-cv-00988): Zydus Lifesciences Limited of India, Zydus Lifesciences Global FZE of the United Arab Emirates and Zydus Pharmaceuticals (USA) Inc. ANDAs 221364 and 221365. Notice received July 14. Answered November 11.
Where the cases go from here
The cases are at their earliest stage, with the stay running to November 13, 2029 in all 14. What FDA recommends a generic tirzepatide application contain is set out in its product-specific guidances for Mounjaro and Zepbound, both revised in draft on July 28, 2026, the same day FDA withdrew its 2021 guidance on synthetic copies of peptides first approved as recombinant DNA products. Our post on the July guidances covers both actions.
These are cases about ANDAs, the applications that lead to FDA-approved generic copies of Mounjaro and Zepbound. Each complaint is directed at the named applicants and their proposed generic products, and none addresses products sold for research use.
Sources
- Complaint, Eli Lilly & Co. v. Alembic Pharmaceuticals Ltd., D. Del. No. 1:26-cv-00972 (August 6, 2026), and docket.
- Complaint, Eli Lilly & Co. v. Amneal Pharmaceuticals LLC, D. Del. No. 1:26-cv-00973 (August 6, 2026), and docket.
- Complaint, Eli Lilly & Co. v. Aspiro Pharma Ltd., D. Del. No. 1:26-cv-00974 (August 6, 2026), and docket.
- Complaint, Eli Lilly & Co. v. Biocon Pharma Ltd., D. Del. No. 1:26-cv-00976 (August 6, 2026), and docket.
- Complaint, Eli Lilly & Co. v. Dr. Reddy's Laboratories, Ltd., D. Del. No. 1:26-cv-00977 (August 6, 2026), and docket.
- Complaint, Eli Lilly & Co. v. Eugia Pharma Specialities Ltd., D. Del. No. 1:26-cv-00978 (August 6, 2026), and docket.
- Complaint, Eli Lilly & Co. v. Galenicum Health S.L.U., D. Del. No. 1:26-cv-00980 (August 6, 2026), and docket.
- Complaint, Eli Lilly & Co. v. Hikma Pharmaceuticals USA Inc., D. Del. No. 1:26-cv-00981 (August 6, 2026), and docket.
- Complaint, Eli Lilly & Co. v. Hybio Pharmaceutical Co. Ltd., D. Del. No. 1:26-cv-00982 (August 6, 2026), and docket.
- Complaint, Eli Lilly & Co. v. Macleods Pharmaceuticals Ltd., D. Del. No. 1:26-cv-00984 (August 6, 2026), and docket.
- Complaint, Eli Lilly & Co. v. MSN Laboratories Private Ltd., D. Del. No. 1:26-cv-00985 (August 6, 2026), and docket.
- Complaint, Eli Lilly & Co. v. Rio Biopharmaceuticals, Inc., D. Del. No. 1:26-cv-00986 (August 6, 2026), and docket.
- Complaint, Eli Lilly & Co. v. Sandoz Inc., D. Del. No. 1:26-cv-00987 (August 6, 2026), the source of the relief described above, and docket.
- Complaint, Eli Lilly & Co. v. Zydus Lifesciences Global FZE, D. Del. No. 1:26-cv-00988 (August 6, 2026), and docket.
- FDA, Paragraph IV Patent Certifications list (as of October 27, 2026), first submission dates, ANDA counts and last qualifying patent expirations for tirzepatide.
- FDA Orange Book, patent and exclusivity data for Mounjaro, NDA 215866, and for Zepbound, NDA 217806.
- 21 U.S.C. 355, the Paragraph IV certification at subsection (j)(2)(A)(vii)(IV), the 30-month stay at (j)(5)(B)(iii) and the new chemical entity provision at (j)(5)(F)(ii).
- 35 U.S.C. 271, infringement by submitting an ANDA at subsection (e)(2)(A).